Drug intelligence / Profile preview

rBCG-interferon alpha-2b

Development stage: Preclinical
Lead developer: ImmunityBio
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravesical

Overview

**rBCG-interferon alpha-2b** is an experimental live recombinant *Mycobacterium bovis* bacillus Calmette-Guérin immunotherapy engineered to synthesize and secrete human interferon-alpha 2b. The construct uses a mycobacterial expression system incorporating an alpha-antigen secretion signal and an interferon-alpha 2b transgene. It was evaluated preclinically as a potential intravesical immunotherapy for bladder cancer, where it enhanced peripheral-blood mononuclear-cell proliferation, interferon-associated immune activation, and cytotoxicity against human bladder cancer cell lines relative to wild-type BCG. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1905993/))

Other names: rBCG-IFNα-2brecombinant bacillus Calmette-Guérin expressing human interferon-alpha 2brecombinant bacillus Calmette-Guérin secreting human interferon-alpha 2b

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on rBCG-interferon alpha-2b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rBCG-interferon alpha-2b.

Explore the full profile